Chemed Corp. (CHE) VP Naomi C. Dallob Sells 750 Shares
Chemed Corp. (NYSE:CHE) VP Naomi C. Dallob sold 750 shares of Chemed Corp. stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $222.09, for a total value of $166,567.50. Following the completion of the transaction, the vice president now owns 9,097 shares in the company, valued at approximately $2,020,352.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.15. The company had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. Chemed Corp.’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.73 earnings per share.
Several equities research analysts have weighed in on CHE shares. TheStreet downgraded Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Royal Bank Of Canada raised their price target on Chemed Corp. to $232.00 and gave the stock a “sector perform” rating in a report on Tuesday. KeyCorp reissued a “hold” rating on shares of Chemed Corp. in a report on Friday, October 27th. Zacks Investment Research downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. raised their price target on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $236.00.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock valued at $357,341,000 after purchasing an additional 1,954,653 shares during the period. Vanguard Group Inc. grew its position in shares of Chemed Corp. by 1.9% in the second quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock valued at $374,435,000 after purchasing an additional 34,938 shares during the period. Acadian Asset Management LLC grew its position in shares of Chemed Corp. by 1.3% in the second quarter. Acadian Asset Management LLC now owns 579,170 shares of the company’s stock valued at $118,454,000 after purchasing an additional 7,636 shares during the period. State Street Corp grew its position in shares of Chemed Corp. by 1.8% in the second quarter. State Street Corp now owns 453,605 shares of the company’s stock valued at $92,782,000 after purchasing an additional 8,238 shares during the period. Finally, Voya Investment Management LLC grew its position in shares of Chemed Corp. by 39.7% in the second quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock valued at $43,926,000 after purchasing an additional 61,056 shares during the period. 97.24% of the stock is owned by institutional investors and hedge funds.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.